Adma Biologics (ADMA) Net Cash Flow Growth (3y) (2016 - 2025)
Adma Biologics (ADMA) Net Cash Flow Growth (3y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,911.11 Bn | 1,911.05 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.81 Bn | 463.02 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.92 Bn | 115.68 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 32.17% |
| 10 | Adma Biologics | 2.03 Bn | 1.94 Bn | 88.82 Mn | -20.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -20.18% |
| Sep 30, 2025 | -18.18% |
| Jun 30, 2025 | 45.68% |
| Mar 31, 2025 | -54.83% |
| Dec 31, 2024 | -0.48% |
| Sep 30, 2024 | 42.29% |
| Jun 30, 2024 | 61.27% |
| Mar 31, 2024 | -44.18% |
| Dec 31, 2023 | -82.47% |
| Sep 30, 2023 | 39.64% |
| Jun 30, 2023 | 35.94% |
| Mar 31, 2023 | -30.70% |
| Dec 31, 2022 | 64.22% |
| Sep 30, 2022 | 11.90% |
| Jun 30, 2022 | -31.99% |
| Mar 31, 2022 | 56.07% |
| Dec 31, 2021 | 41.79% |
| Sep 30, 2021 | 14.48% |
| Jun 30, 2021 | -39.42% |
| Mar 31, 2021 | 33.06% |